BiotechTube

Prismocitrate 18

Phase 3Recruiting
1 views this week 0 watching⚡ Active📊Featured in Mid-Cap Catalyst Watch
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Regional Citrate Anticoagulation (RCA)

Conditions

Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury (AKI)

Trial Timeline

Jul 12, 2024 → Dec 1, 2026

NCT ID
NCT05399537

About Prismocitrate 18

Prismocitrate 18 is a phase 3 stage product being developed by Baxter for Regional Citrate Anticoagulation (RCA). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05399537. Target conditions include Regional Citrate Anticoagulation (RCA), Continuous Renal Replacement Therapy (CRRT), Acute Kidney Injury (AKI).

What happened to similar drugs?

0 of 2 similar drugs in Regional Citrate Anticoagulation (RCA) were approved

Approved (0) Terminated (1) Active (1)
❌Prismocitrate 18BaxterPhase 3
🔄AXS-02 (oral zoledronate) + PlaceboAxsome TherapeuticsPhase 3

Hype Score Breakdown

Clinical
17
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT05399537Phase 3Recruiting
NCT02860130Phase 3Terminated

Competing Products

6 competing products in Regional Citrate Anticoagulation (RCA)

See all competitors
ProductCompanyStageHype Score
AZD2936AstraZenecaPhase 2
42
Zoledronic acid + PlaceboNovartisPhase 2
31
Ribociclib + Fulvestrant + Anastrozole + Letrozole + ExemestaneNovartisPhase 2
42
PregabalinPfizerPre-clinical
18
Prismocitrate 18BaxterPhase 3
29
AXS-02 (oral zoledronate) + PlaceboAxsome TherapeuticsPhase 3
33